Health Canada Makes Clinical Information on Medical Devices Publicly Accessible
![Health Canada Makes Clinical Information on Medical Devices Publicly Accessible](https://globalregulatorypartners.com/wp-content/uploads/hosting-service-3_875x540.jpg)
Health Canada Makes Clinical Information on Medical Devices Publicly in a significant move toward greater transparency in healthcare, Health Canada (HC), the country’s medical device regulator, has announced that clinical information submitted in support of medical device applications is now publicly available. This development marks a crucial step in empowering healthcare professionals, researchers, and the general public with access to critical data.
FDA Proposes Framework to Bolster Credibility of AI Models in Drug Development
![FDA Proposes Framework to Bolster Credibility of AI Models in Drug Development](https://globalregulatorypartners.com/wp-content/uploads/AdobeStock_503377097-1024x683.jpeg)
The U.S. Food and Drug Administration (FDA) has unveiled a groundbreaking draft guidance aimed at advancing the credibility of artificial intelligence (AI) models in drug and biological product development. This marks a significant milestone as it is the agency’s first formal guidance on AI in this domain, underscoring its commitment to innovation while maintaining rigorous regulatory standards.
ANVISA Publishes Database for Clinical Investigations into Medical Devices
![ANVISA Publishes Database for Clinical Investigations into Medical Devices](https://globalregulatorypartners.com/wp-content/uploads/digital-healthcare-produtos-equipamentos.jpg)
The National Health Surveillance Agency (ANVISA) has announced the launch of a database aimed at clinical investigations related to medical devices. This initiative represents an important milestone in the health sector, promoting greater transparency, efficiency and safety in research carried out in Brazil.
Advantages of Registering Biological and Health Products in Brazil
![Advantages of Registering Biological and Health Products in Brazil](https://globalregulatorypartners.com/wp-content/uploads/WhatsApp-Image-2019-04-25-at-11.04.34.jpeg)
When it comes to health products in Brazil, understanding Anvisa’s regulatory requirements is essential. Two concepts often mentioned in this context are product registration and notification. Although both are necessary processes to guarantee the safety and efficacy of products available on the market, they have important differences in terms of criteria, requirements and procedures.
ANVISA Updates Rules for Clinical Research: Innovation and Agility in Drug Development.
![ANVISA Updates Rules for Clinical Research: Innovation and Agility in Drug Development.](https://globalregulatorypartners.com/wp-content/uploads/112880861.webp)
In November, the National Health Surveillance Agency (ANVISA) announced important changes to its rules for conducting clinical research in Brazil. The new guidelines aim to reduce bureaucratic obstacles, speed up drug development and maintain the strict technical parameters needed to guarantee the safety and efficacy of products. Among the new features is the continuous data submission mechanism, an approach that promises to optimize the analysis and approval processes.
FDA Suggests Collecting data on Ovarian Toxicity in Cancer Drug Trials
![FDA suggests collecting data on ovarian toxicity in cancer drug trials](https://globalregulatorypartners.com/wp-content/uploads/FDA2-1024x576.jpg)
The US Food and Drug Administration (FDA) is recommending that sponsors include the collection of data on ovarian toxicity in the development of cancer drugs.
Integration of the Health Surveillance Fee into the Single Foreign Trade Portal: Timetable and Impacts for Brazilian Trade
![Integration of the Health Surveillance Fee into the Single Foreign Trade Portal: Timetable and Impacts for Brazilian Trade](https://globalregulatorypartners.com/wp-content/uploads/d553a1c54369f97b9e04a9f75955df94-1024x534.png)
Anvisa (the National Health Surveillance Agency), in partnership with the Foreign Trade Secretariat (Secex) and the Federal Revenue Service, has announced the integration of the payment of the Health Surveillance Fee into the Single Foreign Trade Portal (Siscomex). This change is part of a move to centralize and digitize foreign trade processes, offering more agility, transparency and simplicity for importers and exporters dealing with products subject to health surveillance.
Mexican Ministry of Health Advances with SaMD
![Mexican Ministry of Health Advances with SaMD](https://globalregulatorypartners.com/wp-content/uploads/cofepris-2-1024x576.jpg)
The Mexican regulator, COFEPRIS, published the 5.0 edition of the Supplement for Medical Devices in the Mexican Pharmacopoeia, introducing regulatory requirements for Software as a Medical Device (SaMD).
US FDA publishes Permanent Accreditation System Conformity Assessment Program
![Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA](https://globalregulatorypartners.com/wp-content/uploads/FDA-Social-Graphic-1080x675-1-1024x640.png)
In September 2023, the US FDA issued regulatory updates, to the guidance on the Innovative Devices Program and preliminary guidance on medical devices associated with weight loss.
Registration holder for Medical Devices Imported from Mexico
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
Registration holder for Medical Devices Imported from Mexico.
Mexico’s Cofepris medical Device and IVD Registration and Approval in Mexico
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
GRP Mexico can help you obtain COFEPRIS medical device registration and approval to sell your product on the Mexican market.
Mexico’s Cofepris has Issued New Guidelines for Changes to Medical Device Registrations
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
![Review of the Draft Technovigilance Standard by COFEPRIS in Mexico.](https://globalregulatorypartners.com/wp-content/uploads/cofepris-1-1.jpg)
In August 2023, Mexican regulators have updated guidance on rules for modifications to medical device registrations that could streamline COFEPRIS reviews.